• CannAssist International’s Xceptor Labs is active player within CBD-based product sector
• Global CBD product market is expected to rise in value from $4.6 billion in 2018 to over $23 billion by 2025
• Xceptor Labs differentiating product range through use, development of proprietary CiBiDinol technology
• CiBiDinol technology covers the oil soluble CBD molecule with a water soluble carrier thereby increasing its bioavailability and enabling easier absorption of product
• Xceptor Labs has recently launched its Xceptol product line, comprised of topical pain creams, CBD-derived capsules, tinctures and pet drops

CannAssist International (OTCQB: CNSC) is a biotechnological pharmaceutical and wellness company which has rapidly garnered a reputation and loyal following due to its innovative technology and proprietary product line, marketed through its Xceptol consumer brand. Founded in May 2017, CannAssist moved to the forefront of the cannabidiol industry following the passing of the 2018 Farm Bill, whereby the United States effectively decriminalized the cultivation and use of hemp and its derivative products. Since then, the global cannabidiol (“CBD”) industry has seen its growth and popularity surge to new heights, set to rise from a market value of $4.6 billion in 2018 to an estimated $23.6 billion by 2025 (https://ibn.fm/PL6PO).

In a sector which has seen its ranks rapidly swell given an influx of new entrants, CannAssist’s wholly owned Xceptor Labs has sought to differentiate itself through the use and development of its CiBiDinol technology. CiBiDinol technology is comprised of a proprietary process specifically designed to address a number of the shortcomings currently afflicting oil-soluble CBD molecules – namely, the delivery, bioavailability and short shelf-life (https://ibn.fm/GfbVM).

Through its unique formulations and technology, CannAssist has succeeded in developing CBD products offering a greater level of predictable potency while allowing for lower dosage requirements. By effectively covering the CBD molecule’s surface and rendering it water dispersible, CiBiDinol allows for more effective absorption of the product through the consumer’s skin and gut, which in turn significantly lowers the amount of CBD needed to achieve the product’s targeted endpoints.

Xceptor Labs has recently begun marketing its CiBiDinol technology-based Xceptol line of topical pain cream products as of September 2020. Comprising five creams which utilize FDA-registered ingredients and are designed to provide localized and fast-acting relief for sore and aching muscles and joints, the products are set to be sold online – through consumer products portal Range Me as well as through a network of international and domestic retail distributors. Meanwhile, the company is planning to raise awareness around the Xceptol product range through an upcoming series of targeted social media campaigns which will feature celebrities and former athletes advocating the product line’s various features. Xceptor Labs has recently added an array of CBD-based capsules, tinctures and pet drops.

CBD products have gained a reputation for their ability to provide medical relief under a variety of conditions while simultaneously excluding the psychoactive effects caused by tetrahydrocannabinol (“THC”). According to a study by the Harvard Health Institute in 2018, CBD products have been habitually used to address a wide gamut of health issues, including insomnia, anxiety, and physical pain, among various others. Meanwhile, increased legalization initiatives and growing consumer acceptance around the world have spurred further interest and innovation within the sector – a trend which CannAssist intends to lead.

Separately, CannAssist has recently revealed that based on the ongoing revenue trends from raw material and retail sales, and Xceptol’s international development, the company expects to generate sales of $5 million in first-year revenues.

For more information, visit the company’s website at www.CannAssistInternational.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC

• Net Element plans to radically transform its business model following completion of merger with Mullen Technologies, converting into pure-play EV manufacturer
• Electric vehicles are set to account for 3% of global vehicle sales in 2020
• Governments have increasingly pushed for electric vehicle adoption as key pillar underpinning environmental objectives; the UK just announced ban on sale of fossil-fuel powered cars by 2030
• NETE CEO Oleg Firer recently elaborated on challenges of entrepreneurship, role of diplomacy within modern corporate management

Net Element (NASDAQ: NETE) presents its stakeholders with a unique business proposition: Within its role as a global financial technology and value-added solutions group, Net Element provides its customers with electronic payments solutions spanning across point-of-sale, e-commerce and mobile devices, both in the United States and in selected emerging markets. It is under this very model that the company has seen its fortunes rise exponentially, with revenues climbing from $0 in 2013 to $65 million as of 2019. Under the leadership of CEO Oleg Firer, a veteran entrepreneur and corporate turn-around specialist, Net Element has recently sought to radically transform its business model, with plans to jettison its long-standing payments business in favor of converting into a pure-play electric vehicle (“EV”) manufacturer (https://ibn.fm/kdqCv). On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately held Mullen Technologies Inc., a Southern California-based electric vehicle company. The transaction, which will be in the form of a stock-for-stock reverse merger where Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company, will mark Net Element’s entry into one of the fastest-growing sectors within the global economy (https://ibn.fm/dYUea). According to the International Energy Agency, sales of electric vehicles topped 2.1 million units globally in 2019, boosting the global stock to 7.2 million electric vehicles. The sector has evidenced a precipitous surge in growth, with electric vehicles – which accounted for 2.6% of global car sales and about 1% of the global automotive stock in 2020—registering a 40% year-on-year increase in sales last year; meanwhile, electric vehicles sales are anticipated to continue growing relative to those of their internal combustion engine-powered peers, accounting for approximately 3% of global car sales in 2020. In addition to their growing popularity among automobile purchasers, electric vehicles have gained in prominence given that they represent a key technology to be used in high-profile global initiatives: the reduction of air pollution in densely populated areas and in the assistance of achieving greenhouse gas emissions reduction objectives. To date, 17 countries have announced 100% zero-emission vehicle targets, with the UK recently announcing a domestic ban on the sale of fossil fuel-powered vehicles by 2030 (https://ibn.fm/Ne5dU). While Net Element’s segue into the electric vehicles space demonstrates remarkable foresight given the growth prospects attributed to the sector, it does not come without its own inherent challenges – ensuring corporate management ‘buy-in’ may be just as critical as a sector’s long-term potential, according to CEO Oleg Firer. “Being a chief executive in business is very similar to being a diplomat,” Firer noted. “Managing a business in today’s environment requires constant negotiations at the executive levels and diplomatic approach to mid-management. One of my favorite diplomatic approaches to management is an ability to promote and seed an idea or a solution within, where your colleagues begin to believe in it as much as they begin present and solicit this idea or solutions rest of the group.” Given Firer’s stellar track-record at the helm of various companies – which has included being awarded Inc Magazine’s prize as the United States’ fastest growing private sector company in 2012, the future looks bright for Net Element as it prepares to take on new challenges amidst the company’s planned foray into the world of electric vehicles. For more information, visit the company’s website at www.NetElement.com. NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

• Agriculture biotech providing natural organic biopesticide, alternative solution to banned synthetic chemicals.
• Company focused on high-value crops in North, South American market with view to expanding.
• MBRO delivers unique product larger producers failed to deliver, offers robust growth potential

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) COO Colin Bletsky was featured in a recent SmallCap-Investor interview (https://ibn.fm/Ax1Bd). During the interview, Bletsky discussed the company and its unique value proposition and ambitious plans for the future. MustGrow is an innovative agriculture biotech company providing natural, science-based biological solutions to replace synthetic chemicals used in high-value crops such as fruit and vegetables. In his comments, Bletsky explained that a rigorous scientific process stands behind the company’s technology. According to Bletsky, MustGrow has invested more than $10 million dollars developing its proprietary technology. The company has also conducted an estimated 110 studies in the field and worked with third-party companies. This significant investment of time and money has led to around 100 of the patents MustGrow now owns. Although a result of cutting-edge scientific research, MustGrow’s end product comes from nature; it is organic and natural, Bletsky said MustGrow Biologics is open to partnerships with both big players and mid-size companies in the marketplace, which is increasingly trying to gain access to this novel technology. Bletsky believes that although the company is a threat to conventional chemical producers, it also represents an excellent partnership opportunity. “We are potentially a partner to any one of those companies because we provide a solution that they don’t have right now,” he said. “We have a lot of field data and study showing that we can compete on efficacy and on consistency, and when we look at the marketplaces we’re targeting, we can actually compete on price.” As consumers and growers demand healthier, safer and easier-to-use alternatives, chemical products are attracting more scrutiny, with countries continuing to deregister some of them. “When we look at everything down the road, we do believe that we have a good opportunity with or without those chemical companies working with us. Even if they’re working against us, we have a unique position,” Bletsky observed. Although currently focused on higher-value crops where many chemistries are being banned or deregistered in some parts of the world, Bletsky also confirmed that MustGrow is looking into expanding coverage to include potatoes, onions, garlic, bananas and pulses such as chickpeas and lentils. With an existing registration for the granulated formulation in the United States and Canada, MustGrow Biologics shifts the focus to the second-stage product, liquid-based formulation. The company is in the process of registration with relevant authorities in North America and South America, which Bletsky expects to be completed in 2021; the intended registration process in Europe may take longer due to regulation, he added. As a tightly held company with 22 out of 37 million outstanding shares held by MustGrow management and advisors, and a small market capitalization ranging from $13 to $15 million, Bletsky believes that MustGrow Biologics offers a unique advantage to investors. Confident that a lot of opportunity exists in the targeted $65 billion pesticide market, of which the fruit and vegetable market is roughly half, he believes the company is ready to start on the path of rapid growth. For more information, visit the company’s website at www.MustGrow.ca. NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

• CNS Pharmaceuticals featured in audio broadcast distributed to thousands of syndication points.
• Berubicin IND accepted for review by FDA
• Phase 1 trial showed 44% of patients experiencing clinical benefit of stable disease or better
• Adult Phase 2 trials to commence in Q1 2021

The IND filing for brain cancer drug Berubicin has been accepted for review by the U.S. Food and Drug Administration (“FDA”), reports CNS Pharmaceuticals (NASDAQ: CNSP), the company now responsible for the drugs’ development. That news was featured in a recent syndicated NetworkNewsAudio (“NNA”) broadcast, which covered CNS Pharmaceuticals’ recent submission of an Investigational New Drug (“IND”) application to the FDA for Berubicin. The broadcast also detailed the company’s plans to commence adult Phase 2 trials of the drug during the first quarter of 2021. Since review of the IND application has not been completed, it may seem a little strange that CNSP is already looking ahead to Phase 2 clinical trials. However, Berubicin has already been the subject of Phase 1 trials, which are focused on finding the safest effective dose of a drug. In 2006, Reata Pharmaceuticals, a clinical-stage biopharmaceutical company conducted clinical trials that have had quite encouraging results. Fortuitously, 11 of the 25 cancer patients who were treated with Berubicin and were available for evaluation in those initial clinical trials “experienced a statistically significant improvement in progression-free survival” (https://ibn.fm/OgkZB). Moreover, “one patient experienced a durable complete response, which is defined by the National Cancer Institute as the disappearance of all signs of cancer in response to treatment.” This means that that patient has suffered no recurrence and has remained cancer free for more than 13 years. Two other patients saw reductions in tumor size of up to 80%. Berubicin has been developed to treat glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. The drug is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs. Anthracyclines are also effective against more types of cancer than any other class of chemotherapeutic agents. They are designed to utilize natural processes to induce deoxyribonucleic acid (“DNA”) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. In effect, Berubicin prevents cancerous cells from replicating. The Phase 2 clinical trials will be conducted in conjunction with WPD Pharmaceuticals Inc. Additionally, there are plans afoot for WPD Pharmaceuticals to commence a first-ever Phase 1 trial with children in the near future. This pediatric trial will be conducted at Children’s Memorial Health Institute, the largest pediatric hospital in Poland. CNSP is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. In June 2020, the company hired U.S.-based Pharmaceutics International Inc. (“Pii”) and Italian BSP Pharmaceuticals S.p.A. (“BSP”) to handle production of the drug. Synthesis of the Berubicin Active Pharmaceutical Ingredient (“API”) had already been completed, and the API has been delivered to the two manufacturing entities; both have now prepared an injectable form of Berubicin to be used in the clinical trials. With the production process fully underway, the company is a step closer to getting its IND approved by the FDA. With this dual-track approach to manufacturing, the company reduces the risk of failing to meet its clinical timeline. Moreover, situating production in Europe as well as the United States provides localized availability of Berubicin for the upcoming Phase 1 pediatric and Phase 2 adult studies in Poland and the U.S. Phase 2 trials. Glioblastoma is one of the most aggressive primary brain cancers in adults, with approximately 13,000 new patients diagnosed each year in the U.S.—the highest diagnosis rate of all malignant brain tumors. An effective way of fighting this pernicious affliction is sorely needed. For more information, visit the company’s website at www.CNSPharma.com NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Financial numbers show revenues stay level, gross margins up and operations expenses down.
• Company continues focus on primary mission of applying artificial intelligence to precision medicine, drug discovery.
• POAI subsidiaries all showing progress, growth in key areas.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its Q3 2020 financial report along with an update of company accomplishments and achievements (https://ibn.fm/HCpQM). In the report, POAI CEO Dr. Carl Schwartz noted milestones for each of the company’s subsidiaries: Helomics, TumorGenesis, Soluble Biotech and Skyline Medical. “Our operating cash improved over the first nine months of 2020 as a result of an improvement in operating expenses, if the non-cash expense for goodwill impairment is excluded, continued new sales of our STREAMWAY Systems, which provide an annuity-like revenue stream from ongoing sales of disposables, and proceeds from equity offerings, indicating investor confidence in our emerging precision medicine business,” said Schwartz. “Concurrently, we are taking the necessary steps to manage our balance sheet, including reducing our accounts payable and reducing our derivative liability by amending a settlement provision for certain outstanding warrants. “Management continues to focus the majority of its resources on the company’s primary mission of applying artificial intelligence to precision medicine and to drug discovery,” Schwartz continued. “Our approach and the mediums used to replace rats and mice in preliminary cancer studies are working in three of our operating subsidiaries, Helomics, TumorGenesis and Soluble Biotech.” In the report, Schwartz noted the following company milestones:

• Signed first contract with a pharmaceutical company for protein expression, solubility studies
• Completed asset purchase of Quantitative Medicine (“QM”), a biomedical analytics and computational biology company
• Sold 15 STREAMWAY(R) systems

In addition, POAI reported its Q3 revenues — $0.5 million — were level with the same quarter last year; revenues were primarily driven by sales of Predictive Oncology’s proprietary STREAMWAY product line. In addition, gross margin was 64% in the third quarter of 2020 compared with 60% in Q3 2019, general and administrative expenses declined 15% to $2.2 million in Q3 2020, and operations expenses slightly decreased in the same period due to lower costs related to staff, including share-based compensation. Regarding each of POAI’s subsidiaries, Schwartz made the following comments:

• Helomics: “We are making steady progress in our Helomics division with the launch of a restructured clinical test offering to clinicians for ovarian cancer. Our project with UPMC-Magee Womens Hospital, analyzing the genomic and drug response profiles of women with ovarian cancer to build predictive models’ terms of therapy response, is close to completion. We are also in discussions with several pharmaceutical companies about partnerships that will monetize our efforts.”
• Soluble Biotech: “We signed our first contract with a pharmaceutical company for protein expression and solubility studies. Importantly, this win validates our investment in state-of-the-art lab equipment and expanded facilities. We are working judiciously to secure additional contracts with other biotechnology and pharmaceutical companies.”
• TumorGenesis: “We introduced our Ovarian Cell Line Media at the BIO-Europe Digital Conference where numerous researchers learned from us how they can isolate and successfully culture ovarian cancer cells that previously could not be cultured. Cornell University (Weill) Medical School and TumorGenesis are collaborating to help identify the best culture media for the studying of mutations that increase the risk of ovarian, breast and other types of cancers.”
• Skyline Medical: “[This] division continues to be self-sustaining, from an operating cash perspective, as sales of new waste fluid management systems and recurring sales of disposables to support those systems more than cover the operating expenses and capital needs of this segment of our business. Importantly, sustaining and even modestly growing this division provides us with cash we need as we accelerate the precision medicine components of our business.”

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow. For more information, visit the company’s website at www.Predictive-Oncology.com NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• RYAH Group is a technological leader in the plant-based treatment market with its unique combination of proprietary IoT devices and data analytics, supported by patented AI technology
• The company’s products pair a growing ecosystem of therapeutic plants with top-rated apps, devices and services
• RYAH offers a complete remote dosage delivery and dose-monitoring platform based on data-driven analytics supported by prescribing doctors and their patients
• The company is finalizing its anticipated listing on the Canadian Securities Exchange
• RYAH holds a unique position on the $100.3 billion medical plant market, with the potential to capture footholds in both the IoT and Data Intelligence industries

RYAH Group is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions. The company is a leading developer of dose-measuring IoT devices connected with its turn-key platform designed to aggregate and correlate HIPPA-compliant data, suitable to all participants in the patient treatment cycle. The company also specializes in customized, fully integrated, mobile applications and APIs, specifically designed to meet the needs of clinics, clinical trials, government and university research centers, for experimentation and treatment validation – significantly reducing variations in patient-related trials. RYAH unlocks data in the complete therapeutic plant lifecycle – from seed to consumption. Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed to capture anonymous patient dosing and feedback, combined with detailed strain analytics, enabling customized dosing regiments. The company has secured numerous partnerships across the globe, including establishing a footprint in the UK, USA, Australia and Canada, and it has closed several deals in the European Union, as well. The company’s Smart-Inhaler has been selected as the dose-measurement, dose-control and data analytics platform for a UK pain management study and one of the world’s most ambitious and largest clinical trials ever to be conducted in cannabis. Product Portfolio The company’s current portfolio incorporates an ecosystem of IoT products, each consisting of three elements: the device, the medicine-carrying component and the mobile application. The product line currently includes a Smart Dry-Herb Dose-Measuring Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage and a Smart Liquid Dispensing Pen in the prototype stage. RYAH Smart-Inhaler The RYAH Inhaler is the first dry-herb inhaler that allows users to track and control how much is inhaled, providing consistent and predictable results. This inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and dosages, all of which can be customized to individual needs and doctor recommendations, as well as a post-session review mechanism that allows the collection of session data and feedback for further efficacy analysis for customized dosing capabilities. RYAH’s proprietary stainless-steel cartridges for the inhaler use QR technology that contains lab testing and grower information pertaining to the specific strain, thereby mitigating elicit product use and enabling completely transparent remote medicinal analytics, from seed to consumption. In addition, the RYAH Cartridges provide a unique closed-loop recurring revenue opportunity for the company, as the RYAH Inhaler only works with this type of proprietary cartridges that licensed partners fill with medicine. The partners benefit from all the back-end data, providing them access to consumption habits, statistics and other data on patient preferences. RYAH Smart-Patch The RYAH Smart Transdermal Patch is a lightweight, reusable, mobile-controlled patch used for site-specific therapies. The Patch is an Electronic Topical Delivery Patch system intended for recommendation and administration by pain relief professionals and physical and occupational therapists. The patch data and the heating element is completely IoT and controlled by RYAH’s proprietary smartphone applications, which allows scheduling and ‘boosting’ medicine release, on-demand. RYAH Smart-Pen The RYAH Pen is an app-controlled liquid dispenser designed to provide a precise mix of up to three medicine components to create an ‘entourage effect’, enabling customized, wide-spectrum recommendation opportunities by licensed clinicians. The Smart-Pen will feature cartridges that contain CBD, THC and other isolates such as flavonoids or vitamins, or other solutions. There is a built-in mechanism designed to control usage based on recommended dosing schedules. RYAH MD RYAH MD serves as a remote and interactive patient-doctor collaboration and dosing administration platform. Doctors can remotely set dosage amounts for their patients, creating digital prescriptions for the RYAH IoT devices and tracking patient usage in real-time. RYAH MD offers features that include real-time monitoring, appointment booking, doctor-patient video calls and science-based strain recommendations, as well as promoting a better understanding of the effects and benefits of those recommendations among patients. Information is gathered from all of the RYAH devices. PotBot App The PotBot App is a medical cannabis education mobile application that leverages patented AI technology to capture structured and unstructured data to assist patients in learning about various treatments in plant-medicine based on their efficacy goals. The PotBot App is currently one of the top-rated medical cannabis educational mobile applications on the Apple App Store in the United States, with over 300,000 downloads. Through the combination of peer-reviewed and empirical data, the PotBot App provides detailed information on the targeted and tested cannabinoid levels and associated strains from cannabis patients. The result is personalized and driven by data to inform patients of potential product matches associated with similar ailments and efficacy goals. Market Outlook RYAH holds a unique position in the $100.3 billion medical plant market, with the potential to capture and capitalize on growth opportunities made available by both the IoT and Data Intelligence sectors. In 2018, the global IoT market was valued at $212.1 billion, and it is expected to grow exponentially to $1.3 trillion by 2026, registering a CAGR of 25.68%, according to Verified Market Research (https://ibn.fm/XtkPZ). Management Team Dr. Boris Goldstein, Ph.D., is the founder and Chairman of RYAH Group. He is a seasoned entrepreneur, investment banker and venture capitalist. He started his career as the founder of Software House HT, which grew into a worldwide corporation with over 40 offices in 17 countries. Since then, Goldstein has founded and served on the boards of directors and advisory boards for numerous companies in Silicon Valley and Silicon Alley. Goldstein brings experience in fundamental research, investment and technology, authoring multiple patents and books. Gregory Wagner, MBA, is Chief Executive Officer and Director of RYAH Group. He has over 20 years of experience in global financial markets and entrepreneurship. Wagner has held executive roles in the United States and London. He has co-founded and built several startups from the ground up. His current licensures and degrees include FINRA Series 7, 63, 24 and 55, as well as an MBA from Fordham University. Wagner received a Certification in Innovation and Strategy from Harvard University. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• SRAX to host 13th Annual LD Micro Main Event on December 14-15, 2020 via its SRAX Virtual Events SaaS platform
• Conference will feature over 250 company presentations, interviews include Shaquille O’Neal and 2020 presidential candidate Brock Pierce
• 2 million+ small-cap investors invited from SRAX’s active investor base

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, will be hosting the 13th Annual LD Micro Main Event on December 14-15, 2020 via its Sequire Virtual Events SaaS platform. Over 250 companies are scheduled to present to a potential audience of over 2 million invited guests. Attendees will have exclusive access to interviews with Shaquille O’Neal and 2020 presidential candidate Brock Pierce along with other influential panelists across the small-cap space. Since being acquired by SRAX, LD Micro – already a leader in small- and micro-cap conferences – has gained access to the largest active base of micro-cap investors in the world at over 2 million and counting. Since its inception in 2006, LD Micro has grown from a newsletter into a prominent portal that provides exclusive intraday information covering North American stocks with market capitalizations between $50 million and $300 million. The LD Micro Main event this year is set to be one of the company’s most ambitious endeavors in its history, set to bring together millions of potential investors with companies in the flourishing micro-cap space. “I think the Main Event will be the first virtual conference this year that is engaging instead of repetitive,” said LD Micro Founder and CEO Chris Lahiji (https://ibn.fm/bAOws). “There have been too many 20-minute PowerPoints, and investors have lost the desire to watch one more of the same thing. We intend to showcase something different.” Besides its all-new presentation format, the conference will be presented on Sequire, SRAX’s SaaS platform that leverages data analytics for public companies. Tailored to the investment industry, Sequire helps public companies unlock valuable data and insights that can be used to create and activate marketing campaigns in order to attract new investors and engage existing shareholders. “With the launch of this virtual conference, we are one step closer to our mission of creating the most comprehensive platform for issuers,” said SRAX Founder and CEO Christopher Miglino. “We believe this conference will be a success for both the investors and the issuers in the Sequire community, and we look forward to the expansion of the LD Micro audience.” Investor relations in recent years have undergone a rapid transformation with the advent of data-based platforms that allow public companies to track their investors’ behaviors and trends. The movement is projected to continue at a rapid pace, positioning SRAX favorably in the investor relations industry, set to radically transform from innovations in the collection and application of investor data. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• BRSF enhances executive team with new strategy, marketing VPs.
• New market opportunity created with demand for remote EEG testing due to COVID-19.
• Brain Scientific has developed NeuroCap(TM), a revolutionary, hospital-grade disposable EEG headset.

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, strengthened its executive team with the appointment of two proven sales and marketing figures. The two management additions include Amy Griffith, the new vice president of strategy and business development, who will lead the development of strategic and tactical initiatives (https://ibn.fm/Stz6j), and Stuart Bernstein, the new vice president of marketing, who will be responsible for BRSF’s marketing strategy (https://ibn.fm/yfZYU). The strategic move is designed to drive Brain Scientific’s revenue growth and expand its commercialization programs by leveraging the newly hired key executives’ wealth of experience and knowledge. As a commercial-stage, healthcare company disrupting the brain diagnostics market, Brain Scientific is committed to the rapid deployment of its unique technology, bringing its NeuroCap, a revolutionary hospital-grade disposable EEG headset, to as many patients as possible as quickly as possible. Recent research indicates that more than one-third of coronavirus patients experience neurologic symptoms, a fact that adds greater urgency to the company’s efforts to bring the device to market. The NeuroCap offers fast testing with limited contact between medical staff and infected patients, a vital feature in the pandemic environment. A leader in the development and commercialization of innovative life-changing technologies for patients, Brain Scientific is poised to seize the market opportunity opened up by the demand for remote EEG testing. To support its ambitious plans for the future, BRSF enhanced its executive team with seasoned industry figures with a proven track record of success. As an established sales expert with years of experience in the medical and healthcare industries, including health giants such as GlaxoSmithKline, Griffith is a key addition to the management team. Griffith brings extraordinary credentials to Brain Scientific as the company continues to grow as the leader in routine EEG testing. Her experience in global marketing positioning will be critical to BRSF’s future success. With extensive expertise in developing new business opportunities and implementing effective sales strategies and impressive background in the neurology market, she will focus on ensuring the company is well prepared to execute on its next phase of growth. Bernstein has more than 30 years of industry experience in marketing, sales and start-up leadership at companies in the medical devices and healthcare space. He has acquired a wealth of knowledge and skills ideal for leading Brain Scientific’s marketing strategy and propelling the company’s growth to new heights. Previously a CEO of BioSignal, an EEG medical device company, Bernstein is a proven industry veteran with in-depth knowledge and expertise necessary to implement a successful go to market strategy. Bernstein will work collaboratively with Griffith to implement business strategies that support future growth. Together they are poised to set Brain Scientific on the path of growth, shaping the future of the brain diagnostics space. For more information, visit the company’s website at www.BrainScientific.com. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Clean Power Capital Corp. (formerly known as Organic Flower Investments Group Inc.) has built a successful holding company model with 10 investments in a variety of sectors, and its most recent investment is focused on the developing hydrogen fuel marketplace
• The state of California, which boasts the world’s fifth-largest economy, is emerging as a hydrogen fuel booster amid global concerns about climate change
• PowerTap Hydrogen Fueling Corp., an investee company of Clean Power, aims to begin building a 500-station fueling network across the state during the next year before advancing into other parts of the country
• Researchers at McKinsey & Company are forecasting that the hydrogen economy could generate $140 billion in annual revenue by 2030 and support 700,000 jobs (https://ibn.fm/Ztdj2).

While President Donald Trump’s administration has attempted to move the United States away from global climate change science efforts to boost alternatives to the petroleum fuel standard, the apparent victory of President-elect Joseph Biden (which, in a contested election, will be settled between Dec. 14 and Jan. 6 as electors’ votes are counted (https://ibn.fm/JWII5) signals a new impetus by the nation to advance renewable fuels’ potential. Biden’s acknowledgment in a presidential debate that he intends to promote alternative fuels drew pleased criticism from Trump, who expected states with significant petroleum-based economies to reject the candidate (https://ibn.fm/jowvE). But one of those states — Pennsylvania — provided what appears to be the decisive returns in Biden’s favor (https://ibn.fm/Z1ySI). Independent of the national stance on climate change, the state of California, which has an economy larger than all but four countries worldwide (https://ibn.fm/4WDxr), continues to develop its own interests in renewable-energy fuels, emerging as a potential driver of clean-energy hydrogen-based systems for automobiles. Investment holding company Clean Power Capital (CSE: MOVE) (FWB: 2K6A) (OTC: MOTNF) sees the developing marketplace as ripe with potential, as evidenced by recent efforts to invest in and provide early-stage financing to businesses aligned with California’s hydrogen fuel market. Clean Power Capital (known prior to November as Organic Flower Investments Group Inc.) currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year as it turned its attention to an equity investment in PowerTap Hydrogen Fueling Corp. that granted it a 90 percent equity interest (https://ibn.fm/ciw9R). PowerTap Hydrogen Fueling is a technology-developing business determined to build a network of hydrogen fuel stations across California and eventually across the country in a phased development approach, utilizing the company’s onsite steam methane reforming (“SMR”) hydrogen production and dispensing modular units, which have the potential to establish an environmentally cleaner hydrogen fueling process than technologies dependent on a significant amount of electricity to produce hydrogen, and to be more cost effective than offsite-produced hydrogen. PowerTap is aiming for an initial launch of 500 fueling stations in California, co-located at existing gas stations and truck stops and dependent on the necessary agreements for their technology installation. At each stage of development, PowerTap plans to help fund its project through available government financing and credits, in addition to equity, debt and convertible debt offerings. The company expects its planned fueling station network building to begin in the final weeks of this month with initial manufacturing to begin in the first quarter of next year and production to continue throughout the year. From San Diego to San Francisco, hydrogen fueling stations are increasing in number and growing in size as California sets ambitious goals to phase out vehicles that run on fossil fuels and replace them with autos that powered by batteries and hydrogen. The state is providing significant financial incentives to help the fuel alternative develop. “In past cycles, there was always something missing,” Matthew Blieske, Royal Dutch Shell’s global hydrogen product manager, told the New York Times recently (https://ibn.fm/LfseG). “There was a policy missing, or the technology wasn’t quite ready, or people were not so serious about decarbonization. We don’t see those barriers anymore.” A recent study by business and economics researchers at McKinsey & Company estimated that the hydrogen economy could generate $140 billion in annual revenue by 2030 and support 700,000 jobs, and that hydrogen could meet 14 percent of total American energy demand by 2050, according to the report (https://ibn.fm/MkGgd). For more information, visit the company’s website at www.CleanPower.Capital. NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• Imagin Medical Inc. uses the standard levels of care for bladder tumor resection and adds advanced technology combined with an FDA-approved imaging agent to display images side-by-side in real-time to provide better cancer visualization, potentially leading to less recurrence
• Hospitals can use their existing endoscopic equipment, as the company’s technology is compatible with almost every model on the market
• The i/Blue™ Imaging System can potentially be used for other minimally invasive procedures, accommodating multiple contrast agents and illumination sources
• Bladder cancer contributes to 4.5% of all new cancers diagnosed and 3% of all cancer-related deaths. It is the sixth most prevalent form of cancer in the United States, with a greater than 50% risk of recurrence
• The company is led by a management team with experience in this industry, including minimally invasive surgery and medical device implementation

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer. The company’s first product is the i/Blue Imaging(TM) System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells. Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources. i/Blue Imaging(TM) System The conventional method used for visualizing bladder cancer during surgery is an endoscopic procedure called a cystoscopy. This procedure uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Blue light cystoscopy uses blue-filtered white light, which addresses the limitations of white light (such as detecting flat tumors and the fine edges that may result in cancerous cells being left behind during removal). Blue light uses a contrast agent that causes cancer cells to fluoresce when illuminated. Surgeons are then able to more effectively visualize and resect the margins of bladder tumors to reduce the risk of recurrence. Notably, the use of the white light is still necessary during a blue-light procedure so that the surgeon can orient their position within the bladder. Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images. The i/Blue Imaging System is unlike other methods available on the market today. It is external to the body and can attach to almost any endoscope model currently in use. This way, hospitals adopting Imagin Medical’s technology have the ability to use their current endoscopes without the need to purchase new equipment. Bladder Cancer Prevalence The company’s initial focus is bladder cancer, which is the sixth most prevalent form of cancer in the United States. In 2020, the number of new bladder cancer cases is expected to total 81,400, accounting for 4.5 percent of all new cancers diagnosed. The death rate in 2020 for cancer deaths associated with the bladder is forecast at 17,980, or 3% of all cancer-related deaths (https://ibn.fm/qLi3l). Bladder cancer also has one of the highest recurrence rates among all forms of cancer, leaving about 600,000 people in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing this issue, and i/Blue demonstrations have indicated that the use of both white and blue light can enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates. Based on Verified Market Research, the global bladder cancer research market was valued at $3.43 billion in 2018. It is estimated to grow with a CAGR of 4.03% through 2026, resulting in a projected $4.71 billion market (https://ibn.fm/rI7G6). Management Team

1. James Hutchens is the Chief Executive Officer of Imagin Medical Inc. He is a proven entrepreneur with over 30 years of experience in management in the medical technology industry. Hutchens served as a managing partner with Origin Partners, a $55 million early-stage venture capital fund. He was also the founder and CEO of both Microsurge Inc. (a venture-backed minimally invasive surgical company) and Choice Therapeutics (an advanced wound-care company). He is a former member of the Board of Directors of the Brigham and Women’s and Faulkner hospitals. Hutchins holds a BS in Business Administration from Boston University.

John Vacha is the company’s Chief Financial Officer. He has 20 years of experience in the health care industry. Prior to Medtronic’s acquisition of Intact Medical Corp. in 2017, Vacha was the company’s President, CEO and a board member for seven years. He is a licensed CPA in Massachusetts. Vacha has an MBA and an MS in Accounting from Northeastern University in Boston. He is also a serving member of the Board of Directors at the South Boston Health Center. He currently has two patents in electrosurgical instrumentation. Michael G. Vergano is the Director of Operations of Imagin Medical. He has been the President of The Harvest Group Inc. since 1998, where he has provided consultant services for startups and major corporations. Vergano has over 30 years of experience in the medical device industry. He has held management positions at Microsurge Inc., Ciba Corning Diagnostics and Boston Scientific Corp. He is currently the holder of 11 medical device patents and holds a BS in Mechanical Engineering from Tufts University. Pam Papineau is the company’s Director of Regulatory Affairs. She has over 30 years of experience in quality and regulatory affairs with Boston Scientific, Baxter and Cogentix. She has served as a consultant on various devices including imaging, endoscopy, orthopedic, GI/GU and cardiovascular applications. Papineau has successfully prepared dozens of FDA pre-market and EU submissions to support CE marking of a broad spectrum of medical devices. She is an ASQ Certified Quality Engineer, a Certified Biomedical Auditor, a Certified Quality Auditor and an ISO 13485:2016 Lead Auditor, and she is certified by the Regulatory Affairs Professional Society – U.S., EU and Canada. Papineau works with the company’s legal counsel to prepare pre-submission meetings with the FDA and activities through the regulatory approval process. For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF